BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014;105:1-7. [PMID: 24534673 DOI: 10.1016/j.antiviral.2014.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, Maher L. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. International Journal of Drug Policy 2017;47:77-85. [DOI: 10.1016/j.drugpo.2017.05.022] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 15.2] [Reference Citation Analysis]
3 Soriano V, Labarga P, Fernandez-montero JV, Mendoza CD, Benítez-gutiérrez L, Peña JM, Barreiro P. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 2017;13:807-16. [DOI: 10.1080/17425255.2017.1351942] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
4 Shmagel KV, Saidakova EV, Shmagel NG, Korolevskaya LB, Chereshnev VA, Robinson J, Grivel JC, Douek DC, Margolis L, Anthony DD, Lederman MM. Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection. HIV Med. 2016;17:581-589. [PMID: 27187749 DOI: 10.1111/hiv.12357] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
5 Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 2016;17:1215-23. [PMID: 27149603 DOI: 10.1080/14656566.2016.1182156] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
6 Dominguez-Molina B, Leon A, Rodriguez C, Benito JM, Lopez-Galindez C, Garcia F, Del Romero J, Gutierrez F, Viciana P, Alcami J, Leal M, Ruiz-Mateos E. Analysis of Non-AIDS-Defining Events in HIV Controllers. Clin Infect Dis 2016;62:1304-9. [PMID: 26936669 DOI: 10.1093/cid/ciw120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
7 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
8 Barreiro P, Labarga P, Fernandez-Montero JV, Mendoza Cd, Benítez-Gutiérrez L, Peña JM, Soriano V. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol 2015;71:63-6. [PMID: 26302484 DOI: 10.1016/j.jcv.2015.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
9 Esposito I, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Benítez-Gutiérrez L, Peña JM, Soriano V. Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. Expert Opin Drug Saf 2015;14:1421-34. [PMID: 26212044 DOI: 10.1517/14740338.2015.1073258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mwatelah RS, Lwembe RM, Osman S, Ogutu BR, Aman R, Kitawi RC, Wangai LN, Oloo FA, Kokwaro GO, Ochieng W. Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast. PLoS One 2015;10:e0132287. [PMID: 26208212 DOI: 10.1371/journal.pone.0132287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Turkova A, Giacomet V, Goetghebuer T, Miloenko M, Nicolini LA, Noguera-julian A, Rojo P, Volokha A, Indolfi G, Giaquinto C, Thorne C. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. Journal of Virus Eradication 2015;1:179-84. [DOI: 10.1016/s2055-6640(20)30504-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
12 Koutsoudakis G, Romero-Brey I, Berger C, Pérez-Vilaró G, Monteiro Perin P, Vondran FW, Kalesse M, Harmrolfs K, Müller R, Martinez JP, Pietschmann T, Bartenschlager R, Brönstrup M, Meyerhans A, Díez J. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. J Hepatol 2015;63:813-21. [PMID: 26070407 DOI: 10.1016/j.jhep.2015.06.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
13 Sede MM, Laufer NL, Quarleri J. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. Int J Antimicrob Agents 2015;46:219-24. [PMID: 26100213 DOI: 10.1016/j.ijantimicag.2015.04.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 De Clercq E. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace: Treatment of hepatitis C accelerating. Rev Med Virol 2015;25:254-67. [DOI: 10.1002/rmv.1842] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
15 Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A. Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep 2015;32:29-48. [PMID: 25315648 DOI: 10.1039/c4np00085d] [Cited by in Crossref: 120] [Cited by in F6Publishing: 121] [Article Influence: 17.1] [Reference Citation Analysis]
16 Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Peña JM. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 2015;11:333-41. [PMID: 25553890 DOI: 10.1517/17425255.2015.998997] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
17 de Mendoza C, Barreiro P, Benitez L, Soriano V. Gene therapy for HIV infection. Expert Opin Biol Ther 2015;15:319-27. [PMID: 25323559 DOI: 10.1517/14712598.2015.967208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
18 Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus JV. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345. [PMID: 25068274 DOI: 10.1371/journal.pone.0103345] [Cited by in Crossref: 169] [Cited by in F6Publishing: 174] [Article Influence: 21.1] [Reference Citation Analysis]
19 Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, Mathews WC. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One 2014;9:e102883. [PMID: 25036553 DOI: 10.1371/journal.pone.0102883] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]